Cingulate and Indegene Announce Joint Commercialisation Agreement
Monday, March 13, 2023
Cingulate and Indegene announced a joint commercialisation agreement to provide commercial support for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder (ADHD), upon approval from the U.S. Food and Drug Administration (FDA).
The agreement includes cross-functional services through an omnichannel marketing approach uniquely designed to successfully manage pre-commercial support during Cingulate’s Phase 3 clinical trials and to effectively commercialise CTx-1301 nationwide following potential FDA approval. Moreover, this agreement provides a clear path to commercialise CTx-1301, upon FDA approval, designed specifically to tackle the unmet needs of $20 billion market by providing the first true, entire-active-day treatment for ADHD.
CTx-1301's unique properties differentiate Cingulate from other products on the market, which aligns well with Indegene's multi-channel approach to physician and patient awareness.
